These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37670359)

  • 1. Total network controllability analysis discovers explainable drugs for Covid-19 treatment.
    Wei X; Pan C; Zhang X; Zhang W
    Biol Direct; 2023 Sep; 18(1):55. PubMed ID: 37670359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total network controllability analysis discovers explainable drugs for Covid-19 treatment.
    Wei X; Pan C; Zhang X; Zhang W
    Res Sq; 2023 Jul; ():. PubMed ID: 37503262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total controllability analysis discovers explainable drugs for Covid-19 treatment.
    Wei X; Pan C; Zhang X; Zhang W
    ArXiv; 2023 Jun; ():. PubMed ID: 35677421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signaling network analysis reveals fostamatinib as a potential drug to control platelet hyperactivation during SARS-CoV-2 infection.
    Osmanoglu Ö; Gupta SK; Almasi A; Yagci S; Srivastava M; Araujo GHM; Nagy Z; Balkenhol J; Dandekar T
    Front Immunol; 2023; 14():1285345. PubMed ID: 38187394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?
    Saha S; Halder AK; Bandyopadhyay SS; Chatterjee P; Nasipuri M; Bose D; Basu S
    Methods; 2022 Jul; 203():564-574. PubMed ID: 34455072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Network analytics for drug repurposing in COVID-19.
    Siminea N; Popescu V; Sanchez Martin JA; Florea D; Gavril G; Gheorghe AM; Iţcuş C; Kanhaiya K; Pacioglu O; Popa LL; Trandafir R; Tusa MI; Sidoroff M; Păun M; Czeizler E; Păun A; Petre I
    Brief Bioinform; 2022 Jan; 23(1):. PubMed ID: 34864885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.
    Fiscon G; Conte F; Farina L; Paci P
    PLoS Comput Biol; 2021 Feb; 17(2):e1008686. PubMed ID: 33544720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing.
    Das AB
    BMC Med Genomics; 2021 Sep; 14(1):226. PubMed ID: 34535131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases.
    Li Z; Wu J; Zhou J; Yuan B; Chen J; Wu W; Mo L; Qu Z; Zhou F; Dong Y; Huang K; Liu Z; Wang T; Symmes D; Gu J; Sho E; Zhang J; Chen R; Xu Y
    mBio; 2021 Oct; 12(5):e0254221. PubMed ID: 34634931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Network Controllability-Based Prioritization of Candidates for SARS-CoV-2 Drug Repositioning.
    Ackerman EE; Shoemaker JE
    Viruses; 2020 Sep; 12(10):. PubMed ID: 32993136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification.
    Li Y; Chu F; Li P; Johnson N; Li T; Wang Y; An R; Wu D; Chen J; Su Z; Gu X; Ding X
    J Ethnopharmacol; 2021 May; 271():113854. PubMed ID: 33513419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates.
    Rodrigues L; Bento Cunha R; Vassilevskaia T; Viveiros M; Cunha C
    Molecules; 2022 Apr; 27(9):. PubMed ID: 35566073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium.
    Gupta RK; Nwachuku EL; Zusman BE; Jha RM; Puccio AM
    PLoS One; 2021; 16(9):e0257784. PubMed ID: 34582497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
    More SA; Patil AS; Sakle NS; Mokale SN
    Virology; 2021 Mar; 555():10-18. PubMed ID: 33421743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis.
    Adhami M; Sadeghi B; Rezapour A; Haghdoost AA; MotieGhader H
    BMC Biotechnol; 2021 Mar; 21(1):22. PubMed ID: 33711981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
    Verma AK; Aggarwal R
    Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.